Aelis Farma SA Total Liabilities
Aelis Farma SA total liabilities. Based on the latest financial reports, Aelis Farma SA (AELIS) has total liabilities worth €9.46 Million EUR (≈ $11.07 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aelis Farma SA (AELIS) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aelis Farma SA (2017–2024)
Total liabilities of Aelis Farma SA from 2017 to 2024. This chart illustrates how Aelis Farma SA's total liabilities have evolved over time, based on quarterly financial data.
Aelis Farma SA Competitors by Total Liabilities
The table below lists competitors of Aelis Farma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luxbright AB
ST:LXB
|
Sweden | Skr8.85 Million |
|
WAPS Co. Ltd
KQ:196700
|
Korea | ₩32.98 Billion |
|
PATERSON RESOURCES LTD
F:U40
|
Germany | €687.06K |
|
Frigo-Pak Gida Maddeleri Sanayi ve Ticaret AS
IS:FRIGO
|
Turkey | TL839.63 Million |
|
Media Investment Optimization SL
MC:MIO
|
Spain | €33.90 Million |
|
Advance Metals Ltd
AU:AVM
|
Australia | AU$1.01 Million |
|
Nanalysis Scientific Corp
V:NSCI
|
Canada | CA$22.05 Million |
|
Focus Lumber Bhd
KLSE:5197
|
Malaysia | RM7.56 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Aelis Farma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Aelis Farma SA assets under control.
Liquidity & Leverage Metrics
Aelis Farma SA Total Liabilities Ratios Explained
Aelis Farma SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.43 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aelis Farma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aelis Farma SA (2017–2024)
The table below shows the annual total liabilities of Aelis Farma SA from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.59 Million ≈ $11.21 Million |
-26.68% |
| 2023-12-31 | €13.08 Million ≈ $15.29 Million |
-32.67% |
| 2022-12-31 | €19.43 Million ≈ $22.71 Million |
-29.13% |
| 2021-12-31 | €27.41 Million ≈ $32.05 Million |
+255.62% |
| 2020-12-31 | €7.71 Million ≈ $9.01 Million |
+28.14% |
| 2019-12-31 | €6.02 Million ≈ $7.03 Million |
+53.59% |
| 2018-12-31 | €3.92 Million ≈ $4.58 Million |
-14.90% |
| 2017-12-31 | €4.60 Million ≈ $5.38 Million |
-- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more